Altimmune (ALT) Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.

Does the media refer more to ABUS or ALT?

In the previous week, Altimmune had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 23 mentions for Altimmune and 20 mentions for Arbutus Biopharma. Altimmune's average media sentiment score of 0.43 beat Arbutus Biopharma's score of 0.41 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	3 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable valuation & earnings, ABUS or ALT?

Arbutus Biopharma has higher revenue and earnings than Altimmune. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$18.14M	35.93	-$72.85M	-$0.43	-8.00
Altimmune	$430K	1,331.43	-$88.45M	-$1.55	-5.19

Which has more volatility and risk, ABUS or ALT?

Arbutus Biopharma has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of ABUS or ALT?

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by insiders. Comparatively, 4.1% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Do analysts recommend ABUS or ALT?

Arbutus Biopharma presently has a consensus target price of $5.50, suggesting a potential upside of 59.88%. Altimmune has a consensus target price of $20.00, suggesting a potential upside of 148.45%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Altimmune	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Is ABUS or ALT more profitable?

Arbutus Biopharma has a net margin of -1,137.65% compared to Altimmune's net margin of -199,076.92%. Altimmune's return on equity of -55.81% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-1,137.65%	-68.18%	-51.55%
Altimmune	-199,076.92%	-55.81%	-50.60%

Does the MarketBeat Community believe in ABUS or ALT?

Arbutus Biopharma received 378 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.73% of users gave Altimmune an outperform vote while only 71.03% of users gave Arbutus Biopharma an outperform vote.

Company	Underperform	Outperform
Arbutus Biopharma	Outperform Votes 434 71.03%	Underperform Votes 177 28.97%
Altimmune	Outperform Votes 56 72.73%	Underperform Votes 21 27.27%

Summary

Altimmune beats Arbutus Biopharma on 12 of the 19 factors compared between the two stocks.